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presented in the guideline. A systematic review was performed on all the information 
about the dosage and frequency of administration found in the summary of product 
characteristics of the different products included in the treatment algorithms. Current 
pricing and reimbursement conditions in Spain of every biologic and chemotherapy 
drug considered in the guidelines were checked. Results: The first scenario, which 
places bevacizumab as first and second line treatment (concept of continuum of 
care) and anti-EGFR antibody as third line out of the four lines considered, yields an 
estimated OS of 20.2 months and total cost of 52,000€ per patient. The second scenario, 
which places bevacizumab as first line treatment and includes anti-EGFR antibody as 
second line in order to rescue the patients who have failed in the previous treatment, 
results in an estimated OS of 25.0 months and total cost of 50,000€ per patient. Finally, 
the third scenario places anti-EGFR antibody available for WT RAS patients as first 
line treatment and bevacizumab as second line out of three lines. When cetuximab is 
chosen as the anti-EGFR first line therapy, estimated OS is 33.1 months and the total 
cost does not exceed 40,000€ . ConClusions: This analysis not only demonstrates 
that the use of more agents does not always assure a better clinical result, but that 
the use of cetuximab as first line treatment in WT RAS mCRC patients stands as the 
most efficient and cost-effective alternative maximizing OS.
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objeCtives: Several platinum-based combination therapies can be used for the 
treatment of non-small lung cancer. According to a recent review, there is no clearly 
superior treatment in terms of effectiveness, the objective of our current study 
was to determine whether treatment with oral vinorelbine plus cisplatin can be 
potentially cost saving for payers, compared to treatment with pemetrexed and cis-
platin. Methods: Considering the similar efficacy results of both treatment options 
in non-squamous non-small cell lung cancer patients (NS-NSCLC), as reported in a 
randomized phase II study (NAVoTRIAL01), a cost minimization analysis was con-
ducted across 12 European countries (Austria, Czech republic, Denmark, Finland, 
France, Germany, Greece, Norway, Slovak Republic, Spain, Switzerland, the UK). This 
analysis adopted the perspective of the National Health Service. Costs considered 
were those related to anticancer drugs, administration settings (i.e. out-patient/in-
patient/at home), serious adverse events and concomitant medications. All relevant 
costs were calculated based on country-specific reimbursement procedures and 
official tariffs. Results: Using the perspective of the National Health Service, the 
savings per patient treated with oral vinorelbine ranged from € 1,317 in Denmark 
to € 35,001 in Germany. Expressed as a percentage, it varies from 5% (France) to 
83% (Czech Republic). Pooled average costs for each treatment option across the 
12 countries resulted in an estimated cost saving of € 12,871 per patient favour-
ing treatment with oral vinorelbine plus cisplatin as opposed to treatment with 
pemetrexed plus cisplatin. Sensitivity analysis confirmed the robustness of the 
results. ConClusions: This pan-European economic analysis provides economic 
evidence to support the use of oral vinorelbine instead of pemetrexed in the treat-
ment of NS-NSCLC. Indeed, oral vinorelbine provides similar efficacy and an eas-
ily manageable safety profile at a lower overall cost per patient treated (from the 
perspective of the NHS). These benefits are also supported by a convenient mode 
of administration for the patient.
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objeCtives: The primary objective of this study is to identify the total cost of illness 
(COI) of metastatic NSCLC in the Netherlands during 2006-2012, from a healthcare 
perspective. Secondary objective is to identify whether changes in distribution of 
costs have occurred over the last years. Methods: Patients diagnosed with met-
astatic NSCLC between 1-1-2006 and 31-12-2012, who had full follow-up and no 
registered trial participation were included. Patient charts were provided, and a 
structured chart review was performed using a case report form. Data collection 
started after diagnosis of metastatic NSCLC and ended at patient’s death. Data were 
collected of outpatient visits, clinical attendance, oncolytic drug use, imaging, lab 
tests, radiotherapy and surgery data. Results: In total 65 patients were included 
in this study. On average patients had 22.2 outpatient visits and 14.1 inpatient days. 
Diagnostic lab tests and imaging procedures were performed respectively 18.7 and 
13.0 times on average. Oncolytic drugs were used by 75% of patients; average 6.3 
intravenous administrations and 22.7 subscription days of oral oncolytic drugs. 
Total costs amounted to € 16,304, with oncolytic drugs (€ 6,625) and inpatient days 
(€ 5,104) as the main cost drivers. In comparison with the time-period of 2003-2005 
total treatment expenditures decreased by 53%. Of this total costs of treatment, the 
proportion of costs of oncolytic drugs increased from 16% to 41% and proportion of 
costs for outpatient visits decreased from 52% to 31%. ConClusions: Outcomes 
in this study demonstrate that, compared to a recent study, the average cost for 
metastatic NSCLC has decreased over time in the Netherlands. A shift of main cost 
drivers seem to have taken place from inpatient stays in 2005, to costs of oncolytic 
drugs currently. This shift is possibly related to changes in patient management but 
also due to the increase of total expenditures on oncolytic drugs.
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had to be in unresectable stage IIIB or stage IV and under current anticancer 
treatment at enrollment. The calculations included direct costs for radiotherapy, 
supportive and concomitant medication, involvement of other medical disciplines, 
hospitalisations, transfusions an other more. The total annual cost were in median 
10,098.00€ per patient. In contrast, the median annual cost of BSC in the four inter-
national studies were 29,621.48€ . ConClusions: The results show a significant 
difference in the annual cost from data under real-world-conditions in relation to 
the median cost from the four international studies. A reason for the lower costs 
compared to the referenced studies could be the higher share of less expensive 
outpatient services in the german health system.
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objeCtives: Abiraterone acetate plus predniso(lo)ne (AA+P) and enzalutamide 
(ENZ) are novel anti-androgen therapies for the treatment of metastatic castration-
resistant prostate cancer (mCRPC) that are approved in both the pre-chemother-
apy and post-chemotherapy settings. The aim of this study is to estimate and 
compare the costs associated with two treatment sequences: AA+P followed by 
docetaxel (DOC) chemotherapy and then ENZ (‘AA+P-DOC-ENZ sequence’) versus 
ENZ followed by DOC chemotherapy and then AA+P (‘ENZ-DOC-AA+P sequence’) 
in mCRPC patients with non-visceral metastases. Methods: A health economic 
model has been developed to estimate and compare the cost consequences of 
these two treatment sequences in the UK. Seven health states were considered in 
the model: pre chemotherapy treatment (AA+P or ENZ), active monitoring (before 
and after chemotherapy separately), DOC chemotherapy, post-chemotherapy 
treatment (AA+P or ENZ), best supportive care, and death. Clinical input data 
(e.g., duration of treatment, time to chemotherapy) for the model were derived 
from published pivotal trial results. Costs parameters were derived from avail-
able literature and the manufacturers’ published reimbursement submission 
dossiers. List prices of drugs were used. For each treatment sequence, the model 
estimated total costs and total costs per health state. Results: The total costs 
were estimated to be £75,956 for the ‘AA+P-DOC-ENZ sequence’ and £80,591 for 
the ‘ENZ-DOC-AA+P sequence’ resulting in a total cost difference of £4,636. Pre-
chemotherapy costs of AA+P and ENZ treatment were estimated to be £43,817 
and £48,860, respectively (difference £5,043). With respect to the other health 
states, similar costs were estimated for the two sequences, e.g., post-chemother-
apy costs of AA+P and ENZ treatment were predicted to be £9,481 and £8,974, 
respectively. ConClusions: The results of the health economic model suggest 
that the ‘AA+P-DOC-ENZ sequence’ yields lower total costs than the ‘ENZ – DOC- 
AA+P sequence’ and therefore starting treatment with AA+P may result in cost 
savings.
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objeCtives: Assess the cost-effectiveness of tyrosine kinase inhibitors (TKIs) on an 
EGFR+ NSCLC population under the Brazilian private healthcare system. Methods: 
A cost-effectiveness analysis (CEA), based on a Markov framework with monthly 
cycles, was performed to evaluate costs and effects of gefitinib versus erlotinib 
on an EGFR+ NSCLC population over a 1 year period. Outcomes measured were 
overall survival (OS), progression free survival (PFS), Quality Adjusted Life Years 
(QALYs) and total costs. Direct medical costs were assessed, including treatment 
and genome testing costs. Treatment costs were based on ex-factory prices and 
label defined posologies. Efficacy data was based on a meta-analysis by Gao et 
al. Results: Gefitinib was equivalent to erlotinib regarding effectiveness outcomes, 
showing incremental results of 0, -0.02 and -0.01 for OS, PFS and QALY over a 1 year 
time horizon, respectively. Costs were significantly lower on patients treated with 
gefitinib than on those treated with erlotinib. On a scenario where genome test-
ing was not performed gefitinib showed a total cost of R$ 21,580.56 (US$ 6,916.67) 
while erlotinib showed total costs of R$ 39,393.24 (US$ 12,626.04), resulting in an 
incremental cost of -R$ 17,812.98 (-US$ 5,709.29). Genome testing added R$ 1,000.00 
(US$ 320.51) to both arms, resulting in R$ 22,580.56 (US$ 7,237.36) and R$ 40,393.24 
(US$ 12,946.55). ConClusions: Regarding effectiveness, both TKIs showed a similar 
profile. Those results are confirmed by a recent meta-analysis by Haaland et al. 
Therefore, in this economic model gefitinib and erlotinib showed similar efficacy 
profile with gefitinib representing a less costly treatment choice than erlotinib for 
the Brazilian private healthcare system.
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objeCtives: ESMO Clinical Guidelines for metastatic Colorectal Cancer treatment 
(mCRC) were updated in 2014. The objective is to assess the clinical (measured by 
overall survival, OS) and economic implications of its recommendations from the 
Spanish national healthcare system view. Methods: A calculator was designed in 
order to analyze and compare the clinical and economic outcomes of the scenarios 
